Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
441 articles with Janssen Pharmaceutical Inc.
As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab
Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70.
6/7/2021With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced it will regain worldwide rights to its anti-CD70 antibody cusatuzumab from Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
57.7 percent achieved ≥20 percent improvement in joint symptoms (ACR20) and 53.4 percent achieved complete skin clearance (PASI 100) at one year in COSMOS, the first study of a selective interleukin (IL)-23 inhibitor in a true TNFi-IR patient population
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of Relapsed or Refractory Multiple Myeloma
The CEO Roundtable on Cancer has elected Scott White , Company Group Chairman for North America at the Janssen Pharmaceutical Companies of Johnson & Johnson, to its Board of Directors.
Janssen's Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a promising safety profile according to new data at ASCO
Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Results from Phase 1 study of novel GPRC5DxCD3 T-cell redirecting bispecific antibody demonstrate promising clinical activity and support recommended Phase 2 dose
5/24/2021It was another busy week for clinical trial announcement. Here’s a look.
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn's Disease
Late-breaker is one of 20 Janssen abstracts, 16 of which show the safety profile and efficacy of STELARA in treating Crohn's disease and ulcerative colitis at Digestive Disease Week (DDW) Virtual 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RYBREVANT™ is the first fully-human, bispecific antibody approved in lung cancer Simultaneous FDA approval of a companion diagnostic aids in the identification of exon 20 insertion mutations
Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Findings to be presented at the ASCO Annual Meeting show preliminary efficacy in patients with EGFR-mutated NSCLC and Janssen's commitment to address the need for new targeted therapies for this patient population Janssen to also present data comparing amivantamab monotherapy and real-world therapies in patients with NSCLC with EGFR exon 20 insertion mutations who have progressed after platinum doublet chemotherapy
IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
Janssen presents new data at ASCO showing efficacy of IMBRUVICA® plus venetoclax in previously untreated patients with chronic lymphocytic leukemia, and up to seven-year follow-up results on progression-free and overall survival benefits with single-agent IMBRUVICA®
Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® in combination with aspirin consistently reduced severe vascular events in patients with peripheral artery disease after lower-extremity revascularization compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event.
New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO)
Skin clearance rates were maintained at five years with 55.5 percent of patients achieving an Investigator's Global Assessment score of 0 and 53 percent achieving Psoriasis Area Severity Index 100 response in VOYAGE 2
physIQ, a leader in real-world biosensor data collection and digital biomarkers, announced a new multi-year collaboration to license physIQ’s accelerateIQTM to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
Findings from an analysis of the first 500 patients enrolled in the SPHERE registry found more than three-quarters of pulmonary arterial hypertension patients treated with UPTRAVI® either maintained or reduced their one-year mortality risk score.
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
Collaboration includes exclusive worldwide rights to Cidara’s CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding
New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
Data show more than 50 percent of adults with active PsA achieved complete skin clearance (PASI 100) and more than 70 percent achieved at least 20 percent improvement in joint symptoms (ACR 20)